The Department of Pharmaceuticals reported the status of its three PLI schemes (bulk drugs, pharmaceuticals, medical devices) as of June 2026.
Bulk Drugs PLI (₹6,940 crore): 48 projects approved, 39 commissioned making 28 APIs/KSMs. Investment of ₹5,210.74 crore exceeds the ₹4,330 crore committed.
Penicillin G is being made in India again after about three decades (Lyfius Pharma, Kakinada SEZ). India's first fermentation-based Clavulanic Acid plant has opened at Nalagarh, Himachal Pradesh.
Pharmaceuticals PLI (₹15,000 crore): ₹46,744 crore invested against a ₹17,275 crore target, and 1,21,294 jobs created.
Medical Devices PLI (₹3,420 crore): 57 unique devices, including MRI and CT scanners, now in domestic production.
Domestic manufacture of critical KSMs, Drug Intermediates and APIs
Key: Approved in 2020; ₹6,940 crore over eight years. Covers 41 products, which span 53 import-dependent APIs. Greenfield plants are paid incentives on sales.
Shift towards high-value products: biopharma, complex generics, patented and orphan drugs
Key: Cabinet approval 24 February 2021; ₹15,000 crore; FY 2020-21 to 2028-29. Applicants are grouped by global manufacturing revenue: A (₹5,000 crore+), B (₹500-5,000 crore), C (below ₹500 crore, with an MSME sub-group). 55 selected, including 20 MSMEs.
Cut import dependence in high-end devices
Key: Approved in 2020; ₹3,420 crore. Pays a 5% incentive on incremental sales for five years in four segments: cancer care/radiotherapy; radiology and imaging; anaesthesia, cardio-respiratory and renal care; implants.
Common infrastructure to cut bulk-drug manufacturing cost
Key: ₹3,000 crore (2020), up to ₹1,000 crore per park. Three parks: Una (Himachal Pradesh, 90% central aid as a hilly state), Bharuch (Gujarat) and East Godavari (Andhra Pradesh), each at 70%.
Common facilities for device makers
Key: ₹400 crore, up to ₹100 crore per park; parks in Himachal Pradesh, Tamil Nadu, Madhya Pradesh and Uttar Pradesh.
Move pharma from cost-based to innovation-based growth
Key: ₹5,000 crore, notified 17 August 2023. Includes ₹700 crore for Centres of Excellence at seven NIPERs.
Support pharma MSMEs and clusters
Key: ₹500 crore, FY 2021-22 to 2025-26. Three sub-schemes: APICF, PTUAS and PMPDS.
Greenfield projects highlighted by the Department of Pharmaceuticals, 25 September 2026
| Company | Product | Location | Investment | Detail |
|---|---|---|---|---|
| Lyfius Pharma (Aurobindo subsidiary) | Penicillin G | Kakinada SEZ, Andhra Pradesh | ₹2,270.05 crore | 15,000 MT/yr; 2,353 jobs; over 90% domestic value addition |
| Kinvan Pvt Ltd (DPB Group) | Clavulanic Acid (Potassium Clavulanate) | Nalagarh, Himachal Pradesh | ₹504.68 crore | 400 MT/yr; 465 jobs; India's first fermentation-based plant |
| Andhra Organics (Virchow Laboratories) | Sulfadiazine, Telmisartan, Olmesartan | Pydibhimavaram, Srikakulam, Andhra Pradesh | ₹151.47 crore | 221 jobs; technology developed in-house |
| Meghmani LLP | Para Amino Phenol (Paracetamol KSM) | Dahej, Gujarat | ₹60.46 crore | 13,500 MT/yr |
| Centrient Pharmaceuticals India | Atorvastatin API | Nawanshahr, Punjab | ₹161.13 crore | 206 MT/yr; over 80% domestic value addition |
A Key Starting Material is the raw building block built into a drug molecule. Drug Intermediates are the steps in between. The Active Pharmaceutical Ingredient is the therapeutically active substance that goes into tablets or injections. Bulk-drug PLI targets all three links.
GS Paper 3 > Indian Economy > Industrial policy; PLI schemes
General Awareness > Government Schemes
The biologically active component of a medicine, also called a bulk drug.
A compound such as clavulanic acid that blocks the bacterial enzyme that destroys penicillin-type antibiotics.
A cash incentive paid as a percentage of incremental sales of goods made in India.